Lymphodepletion in Cancer Immunotherapy - Metastatic Breast Cancer Trial Talk

From the Experts

Adoptive cell therapy (ACT) is a category of immunotherapy currently being studied in clinical trials to treat metastatic breast cancer. Types of ACT immunotherapy include CAR-T therapy and TIL therapy.

Receiving any type of ACT immunotherapy is a multi-step process. One process is lymphodepletion — also called lymph-depleting or preconditioning. Typically, lymphodepletion involves the patient receiving a short course of chemotherapy to kill their T cells (a part of their immune system) before they receive the ACT immunotherapy. 

Follow the links below to learn why lymphodepletion is used, the pros and cons of lymphodepletion, research questions about best practices in lymphodepletion, and MBC clinical trials studying ACT immunotherapies. 

What is Lymphodepletion?
Side Effects of Lymph-Depleting Chemotherapy
Research Into Preconditioning Best Practices



for past articles or specific information.